ArticleJournal of neuroendocrinology2026
Cushing's syndrome is associated with an advanced chronotype.
Article in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cushing's syndrome is characterised by chronic glucocorticoid excess that abolishes the physiological circadian cortisol rhythm. We investigated whether this circadian disruption alters chronotype. In a single-centre case-control study, chronotype was assessed using the Munich ChronoType Questionnaire (MCTQ; n = 119) and wrist actigraphy (n = 39) in patients with active Cushing's syndrome, patients in biochemical remission, and healthy controls. The primary outcome was mid-sleep on free days corrected for sleep debt (MSFsc). Multivariable analysis was performed to identify independent predictors of chronotype. Agreement between methods was assessed by Bland-Altman analysis. Patients with active Cushing's syndrome had a significantly earlier chronotype than patients in remission and controls (MSFsc by MCTQ: 2.38 h [IQR 1.22; 3.41] vs. 3.29 h [IQR 2.65; 4.32] vs. 3.73 h [IQR 3.16; 4.08]; p = .007 and p = .0003, respectively; actigraphy: 3.15 ± 0.90 h vs. 4.03 ± 0.96 h vs. 4.46 ± 0.75 h; p = .039 and p = .001, respectively). Chronotype did not differ significantly between patients in remission and controls. In a multivariable quantile regression model, active Cushing's syndrome was an independent predictor of chronotype (1.32 h earlier than controls; p = .049), while age, BMI, psychiatric symptoms and sleep disturbance had no significant influence. Actigraphy confirmed earlier sleep offset and acrophase in active Cushing's syndrome. MCTQ and actigraphy were significantly correlated (Pearson r = 0.619, p = .0003, n = 29); agreement analysis revealed no systematic bias, but a significant proportional bias, reflecting wider dispersion of MCTQ-derived values. Patients with active Cushing's syndrome have an earlier chronotype than patients in remission and healthy controls, as determined by both subjective and objective methods. Chronotype assessment, particularly with the MCTQ, may complement biochemical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.